Supreme PLC has announced that it remains on track to meet the market views for adjusted Ebitda for the fiscal year 2024. The London-listed consumer-goods distributor has provided a consensus of £25.6 million ($32 million) for adjusted earnings before interest, taxes, depreciation, and amortization for the year ending March 31. This shows an increase from £19.4 million in fiscal 2023.

Review of Impact of Proposed Ban on Disposable Vape Devices

Responding to press reports regarding a possible ban on disposable vape devices in the U.K. to combat underage vaping, Supreme PLC has stated that it will conduct a comprehensive review of the impact of any proposed changes over the medium to long term. The company will await further clarity before making any decisions.

Supreme PLC expects that if a ban on disposables is implemented, most of its current consumers will transition to alternative forms of vaping. However, it emphasizes that no new legislation will be put into effect until after a formal government consultation.

Positive Market Response

Supreme PLC's shares have seen a positive market response, with an increase of 2.1% to 96.0 pence as of 0739 GMT.

Hamburg Port Operator Receives Takeover Offer

Sutton Harbour Group Reports Strong Summer Performance

Leave A Reply

Your email address will not be published. Required fields are marked *

Related posts

Ixico Expects Growth Despite Revenue Decline
News

Ixico Expects Growth Despite Revenue Decline

Ixico expects growth despite a decline in revenue, with a rebound in double-digit revenue growth projected for fiscal 20...

International Flavors & Fragrances Shares Rise After Cooperation Agreement
News

International Flavors & Fragrances Shares Rise After Cooperation Agreement

International Flavors & Fragrances (IFF) sees a rise in shares following a cooperation agreement with Icahn Capital. Qua...

Lumen Technologies Inc. Reports Mixed Results for Q2
News

Lumen Technologies Inc. Reports Mixed Results for Q2

Lumen Technologies Inc. announces mixed Q2 results with a net loss, lower adjusted earnings, and decreased revenue. The...

Sanofi Aims for Annual Sales of Over 10 Billion Euros by 2030
News

Sanofi Aims for Annual Sales of Over 10 Billion Euros by 2030

Sanofi sets a target of generating over 10 billion euros in annual sales by 2030, focusing on immunology treatments and...